1280 related articles for article (PubMed ID: 9829753)
1. Antileukemia activity of a natural killer cell line against human leukemias.
Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ
Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753
[TBL] [Abstract][Full Text] [Related]
2. Susceptibility of human leukemia to allogeneic and autologous lymphokine-activated killer cell activity: analysis of 252 samples.
Teichmann JV; Ludwig WD; Thiel E
Nat Immun; 1992; 11(3):117-32. PubMed ID: 1392400
[TBL] [Abstract][Full Text] [Related]
3. Human tumor cell line resistance to chemotherapeutic agents does not predict resistance to natural killer or lymphokine-activated killer cell-mediated cytolysis.
Harker WG; Tom C; McGregor JR; Slade L; Samlowski WE
Cancer Res; 1990 Sep; 50(18):5931-6. PubMed ID: 1975512
[TBL] [Abstract][Full Text] [Related]
4. Rapid killing of actinomycin D-treated tumor cells by human mononuclear cells. I. Effectors belong to the monocyte-macrophage lineage.
Colotta F; Peri G; Villa A; Mantovani A
J Immunol; 1984 Feb; 132(2):936-44. PubMed ID: 6690624
[TBL] [Abstract][Full Text] [Related]
5. Lymphokine-activated killer (LAK) cell purging of bone marrow.
Cramer DV; Long GS
Prog Clin Biol Res; 1990; 333():125-35; discussion 136-7. PubMed ID: 2308977
[TBL] [Abstract][Full Text] [Related]
6. Natural killer-sensitive targets stimulate production of TNF-alpha but not TNF-beta (lymphotoxin) by highly purified human peripheral blood large granular lymphocytes.
Peters PM; Ortaldo JR; Shalaby MR; Svedersky LP; Nedwin GE; Bringman TS; Hass PE; Aggarwal BB; Herberman RB; Goeddel DV
J Immunol; 1986 Oct; 137(8):2592-8. PubMed ID: 3760569
[TBL] [Abstract][Full Text] [Related]
7. Assessment of human natural killer and lymphokine-activated killer cell cytotoxicity against Toxoplasma gondii trophozoites and brain cysts.
Dannemann BR; Morris VA; Araujo FG; Remington JS
J Immunol; 1989 Oct; 143(8):2684-91. PubMed ID: 2477453
[TBL] [Abstract][Full Text] [Related]
8. In vitro generation of human activated lymphocyte killer cells: separate precursors and modes of generation of NK-like cells and "anomalous" killer cells.
Burns GF; Triglia T; Werkmeister JA
J Immunol; 1984 Sep; 133(3):1656-63. PubMed ID: 6611374
[TBL] [Abstract][Full Text] [Related]
9. Human oncogene-transfected tumor cells display differential susceptibility to lysis by lymphokine-activated killer cells (LAK) and natural killer cells.
Lanza LA; Wilson DJ; Ikejiri B; Roth JA; Grimm EA
J Immunol; 1986 Oct; 137(8):2716-20. PubMed ID: 3489774
[TBL] [Abstract][Full Text] [Related]
10. Induction of NK cell activity against fresh human leukemia in culture with interleukin 2.
Lotzová E; Savary CA; Herberman RB
J Immunol; 1987 Apr; 138(8):2718-27. PubMed ID: 3494084
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of in vivo generation of cytotoxic effector cells against tumor in tumor-bearing mice.
Fuyama S; Yamamoto H; Fujii Y; Arai S
Cancer Res; 1986 Nov; 46(11):5548-52. PubMed ID: 2428480
[TBL] [Abstract][Full Text] [Related]
12. Human leukemia-derived cell lines and clones as models for mechanistic analysis of natural killer cell-mediated cytotoxicity.
Zarcone D; Tilden AB; Friedman HM; Grossi CE
Cancer Res; 1987 May; 47(10):2674-82. PubMed ID: 2436754
[TBL] [Abstract][Full Text] [Related]
13. Synergistic potentiation of in vivo antitumor activity of anti-human T-leukemia immunotoxins by recombinant alpha-interferon and daunorubicin.
Yokota S; Hara H; Luo Y; Seon BK
Cancer Res; 1990 Jan; 50(1):32-7. PubMed ID: 2293557
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment of human acute T-cell leukemia in SCID mice using the anti-CD7-deglycosylated ricin A-chain immunotoxin DA7.
Jansen B; Vallera DA; Jaszcz WB; Nguyen D; Kersey JH
Cancer Res; 1992 Mar; 52(5):1314-21. PubMed ID: 1371092
[TBL] [Abstract][Full Text] [Related]
15. Increase in immunogenicity and sensitivity to natural cell-mediated cytotoxicity following in vitro exposure of MCA105 tumor cells to ultraviolet radiation.
Begovic M; Herberman R; Gorelik E
Cancer Res; 1991 Oct; 51(19):5153-9. PubMed ID: 1913641
[TBL] [Abstract][Full Text] [Related]
16. Role of human circulating and tumor-infiltrating lymphocytes in cancer defense and treatment.
Lotzová E
Nat Immun Cell Growth Regul; 1990; 9(4):253-64. PubMed ID: 2215514
[TBL] [Abstract][Full Text] [Related]
17. Differences in target cell DNA fragmentation induced by mouse cytotoxic T lymphocytes and natural killer cells.
Duke RC; Cohen JJ; Chervenak R
J Immunol; 1986 Sep; 137(5):1442-7. PubMed ID: 2943792
[TBL] [Abstract][Full Text] [Related]
18. Lysis of human T cell leukemia virus infected T and B lymphoid cells by interleukin 2-activated killer cells.
Froelich CJ; Guiffaut S
J Immunol; 1987 Dec; 139(11):3637-43. PubMed ID: 2824611
[TBL] [Abstract][Full Text] [Related]
19. Development of a murine lymphoma model system for the characterization of natural killer:tumor cell interactions.
Smithson G; Wolcott RM; Chervenak R
Cancer Res; 1992 Aug; 52(15):4149-56. PubMed ID: 1638530
[TBL] [Abstract][Full Text] [Related]
20. Demonstration of natural antibodies in normal rabbit serum with similar specificity pattern as mouse natural killer cells.
Grönberg A; Hansson M; Kiessling R; Andersson B; Kärre K; Roder J
J Natl Cancer Inst; 1980 May; 64(5):1113-9. PubMed ID: 6966004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
